The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
Sartorius Stedim Biotech (SSB) has announced a €23m ($24.6m) research and development (R & D) programme with funding from local government bodies La Region Provence-Alpes-Cote d’Azur and la Metropole Aix-Marseille Provence, France.
Rumours of an Irish expansion freeze have been greatly exaggerated according to Eli Lilly, which says it remains committed to its Kinsale biomanufacturing site.
The UK’s Biomedical Catalyst funding scheme encourages investors to back innovative biopharma research and should be continued according to the BioIndustry Association (BIA).
Biopharma firms continued to attract US venture capital investment in Q1 according to new analysis by PricewaterhouseCoopers (PwC), which says the number of firms that received backing is encouraging.
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Two venture capital-backed biopharma firms were among the top five investments by European private equity funds in Q4 according to analysis by Dow Jones.
Biotech bodies from around the globe have been calling on their respective governments to provide stimulus packages to compensate for the current difficulties in obtaining credit.
